Drug Description
Each ml of solution for injection or infusion contains 96 million units [MU] (960 micrograms) of filgrastim*.Each pre-filled syringe contains 48 million units (MU) (480 micrograms) of filgrastim in 0.5 ml (0.96 mg/ml).*recombinant methionyl granulocyte-colony stimulating factor [G-CSF] produced in Escherichia Coli (BL21) by recombinant DNA technology.Excipient(s): Each ml of solution contains 50 mg of sorbitol.
Presentation
Solution for injection/infusion (injection/ infusion).Clear, colourlesss solution.
Indications
Filgrastim is indicated for the reduction in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with established cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes) and for the reduction in the duration of neutropenia in patients undergoing myeloablative therapy followed by bone marrow transplantation considered to be at increased risk of prolonged severe neutropenia.
The safety and efficacy of filgrastim are similar in adults and children receiving cytotoxic chemotherapy.
Filgrastim is indicated for the mobilisation of peripheral blood progenitor cells (PBPC).
In patients, children or adults, with severe congenital, cyclic, or idiopathic neutropenia with an absolute neutrophil count (ANC) of 
0.5 x 109
